Loading company…
Modulight Biotherapeutics develops light-activated treatments for neurological disorders.
Founded in 2022 and based in Boston, Modulight Biotherapeutics is developing precision treatments for neurological disorders. Its platform uses light-activated inhibitory GPCR opsins to reduce communication between neurons, with potential applications including epilepsy, Parkinson’s disease, and neuropathic pain. In November 2025, it raised USD 12.2 million in seed funding co-led by LocalGlobe and Jibe Ventures, with other investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in